December 16, 2020
1 min watch
Save
Future RCC research focusing on biomarkers, ‘patient perspective’
In an interview with Healio, Elizabeth Plimack, MD, chief of genitourinary medical oncology at Fox Chase Cancer Center, highlighted several exciting areas of research in renal cell carcinoma.
For instance, volumes of data from randomized trials are fueling the search for biomarkers that can inform treatment, such as those that may predict response to therapy. Additionally, researchers are considering how to improve measuring of patient-reported outcomes to gain insight into the long-term tolerability of these treatments, Plimack said.
Click here for the next video in the series on what oncologists should discuss with patients who are newly diagnosed with RCC.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Plimack reports serving as a scientific advisor for Bristol-Myers Squibb, Genentech, MEI, Merck and Seattle Genetics; conducting data safety monitoring for AstraZeneca, Pfizer and Infinity Pharma; receiving honorarium for CME presentations from ASCO GU, Clinical Care Options, Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, NCCN, The Ohio State University, OncLive, PER, Research to Practice, Spire Learning and University of Hawaii; and receiving grants for clinical research from Astellas, Bristol-Myers Squibb, Genentech and Merck.